David Hare An update on cardiovascular disease, depression and adherence
Pushkal Garg A background to siRNA: Pushkal Garg, Alnylam
Ulf Landmesser How do we identify very high risk patients for PCSK9 inhibition? Part Two
Erik Stroes How do we identify very high risk patients for PCSK9 inhibition? Part One
Gregory G. Schwartz Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Bertrand Cariou PCSK9 and the beta-cell
Jan Albert Kuivenhoven Intracellular actions of PCSK9
Anthony Wierzbicki Back to basics on cost-effectiveness
Henry Ginsberg Where are we with CVD prevention guidelines?
Chris Packard Preventing cardiovascular disease: the value of early signs of cardiac injury
Brian Ference What can we learn from Mendelian randomisation about the impact of lipid lowering on CVD and risk of dysglycaemia?
Rodrigo Alonso Insights from Chile: Rodrigo Alonso, Clínica Las Condes, Santiago de Chile
Raul Santos Insights from Brazil: Raul Santos, InCor-University of Sao Paulo
Francois Mach Outcomes data are critical
Gunnar Karlsson Collaboration between patient associations and healthcare professionals is key
David Hare Many key barriers are amenable to change; new strategies are needed
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?
Anthony Wierzbicki PCSK9 inhibitors: Who and when to treat?
Steve Nicholls Current status of IVUS studies of plaque burden: what next with GLAGOV?
John Chapman PCSK9 inhibition at the limits